Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)

Merle, P.Rimassa, L.Ryoo, B.Cicin, I.Harris, W.Banu, E.Sarker, D.2024-06-122024-06-1220180923-75341569-8041https://hdl.handle.net/20.500.14551/26090ESMO 20th World Congress on Gastrointestinal Cancer -- JUN 20-23, 2018 -- Barcelona, SPAIN[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)Conference Object29104104Q1WOS:000439970900011